Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

trointestinal-derived peptide hormone that has also been associated with reducing food intake and has been studied as an anti-obesity agent. These two gastrointestinal peptides (GLP-1 and PYY) are secreted into circulation by neuroendocrine cells (L cells) as part of a natural homeostatic mechanism that senses nutrient transit through the gastrointestinal tract. Such nutrient sensing and related mechanisms are thought to be enhanced as a result of certain types of bariatric surgery for weight loss and control of diabetes.

LX4211 treatment also produced a 50.2 mg/dL adjusted mean decrease from baseline in triglycerides, consistent with the triglyceride reduction observed in the Phase 2a study in type 2 diabetics.  In addition, LX4211, compared to placebo, produced a significant adjusted mean decrease in serum uric acid (1.52 mg/dL from baseline to last study visit, p=0.005). Serum uric acid is an emerging marker for cardiovascular risk and renal disease.  These data, together with a trend of improved blood pressure observed in the Phase 2a study, demonstrate that LX4211 has effects on multiple cardiovascular and metabolic risk factors.  Also of importance in this study was the safety of LX4211, which showed no hypoglycemia and no abdominal pain or diarrhea, consistent with the favorable safety profile associated with dual inhibition of SGLT1 and SGLT2 by LX4211 in previous clinical trials. Enrollment in Lexicon's ongoing Phase 2b study of LX4211 in patients with type 2 diabetes is on schedule, with results anticipated in the first half of 2012.

"We have now observed results from several clinical studies of LX4211 which consistently support the concept of dual SGLT1/SGLT2 inhibition for the treatment of diabetes and indicate a long-term opportunity in diabetes prevention," said Pablo Lapuerta, M.D., senior vice president of clinical development and chief medical officer. "The favorab
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... An aggressive campaign to reduce the unnecessary ... infection with a dangerous drug-resistant bacteria at The Valley ... or C.diff, is a bacterium that can cause symptoms ... A recent article in the New England Journal of ... the United States " asserts that "C. ...
(Date:2/27/2015)... ON , Feb. 27, 2015 /CNW/ - Covalon Technologies ... medical technologies company, today announced financial results for its ... For the three months ended December 31, 2014, revenue ... the quarter was $229,820 or $0.02 per share.  ... , said "I am very pleased with the significant ...
(Date:2/27/2015)... 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... it acquired Bionik Laboratories, Inc., a Toronto ... to qualified accredited investors of units consisting of its ... approximately $6.2 million. Shares of the Company,s common stock ... under the symbol "DWTPD" until FINRA,s approval of the ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... 6, 2011 The U.S. Food and Drug Administration ... (metastatic) medullary thyroid cancer who are ineligible for surgery ... symptoms. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the thyroid gland, which is located in the neck. ...
... April 6, 2011 Quest Diagnostics Incorporated (NYSE: ... testing, information and services, today announced that the Simplexa™ ... with a bronze award for best new science and ... ceremony last night in New York City. Focus Diagnostics, ...
Cached Medicine Technology:FDA Approves New Treatment for Rare Form of Thyroid Cancer 2FDA Approves New Treatment for Rare Form of Thyroid Cancer 3Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards 2Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards 3
(Date:3/1/2015)... Ticket Down is a reputable source for ... Soldier Field. Deadheads have been anxiously anticipating this blockbuster ... Dead was formed 50 years ago back in the 60s ... until the untimely death of Jerry Garcia in 1995. ... blues, reggae, rock, bluegrass, folk, space rock and country to ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 In a ... Fletcher of Game Change Athlete Development ... Leinert about the benefits of athlete development and player ... of the unique challenges that athletes face and how ... future success. , Fletcher became involved in athlete development ...
(Date:2/28/2015)... March—also known as National Brain Injury ... and others that suspected head injuries, especially concussions, ... , Concussions are a form of traumatic brain ... There are 1.6-3.8 million sports-related concussions per year. ... is a brain injury. Many athletes suffer knee ...
(Date:2/28/2015)... For those people who are unable ... Mesothelioma Applied Research Foundation (Meso Foundation) will broadcast ... starting at 9:30 AM. , The live broadcast is ... can be accessed through any browser on a computer ... Symposium is a unique event that covers important treatment ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2
... -- The cost of health care is a hot-button issue ... that health insurance premiums for individuals vary widely around the ... the United States in 2010 was $215, researchers from the ... vary by up to $300 from state to state. ...
... Hamilton, ON (August 17, 2011) Active children ... effective way of countering dehydration than a sports drink ... That,s particularly important during hot summer weather, says Brian ... Medicine Program at McMaster and principal investigator of the ...
... Patients with clinically diagnosed superficial vein thrombosis (SVT), a blood ... resolves on its own without treatment, are four to six ... often life-threatening condition, according to study results published ... the American Society of Hematology (ASH). Recent ...
... latex allergy in health care workers have demonstrated the ... is by stopping the use of powdered latex gloves. ... latex allergy to powdered latex glove use but were ... workers. Reducing the use of powdered gloves reduced the ...
... Minn. Mayo Clinic has received investigational ... the Food and Drug Administration ( http://www.fda.gov/ ... mobilize the body,s defense mechanisms to destroy ... first aimed at preventing cancer recurrence. The ...
... (HealthDay News) -- Many drugs already approved to combat certain ... other seemingly unrelated health problems, a new study indicates. ... computers to pair drugs with all illnesses for which they ... for drug repositioning -- or the use of existing drugs ...
Cached Medicine News:Health News:Cost of Health Coverage in U.S. May Depend on Where You Live 2Health News:Common vein condition increases risk for developing life-threating blood clots 2Health News:Using powder-free latex gloves reduces latex allergy rate in health care workers 2Health News:Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines 2Health News:New Uses Found for Old Drugs 2
... Guidant Contak Renewal 3 cardiac ... tachyarrhythmia therapy and cardiac resynchronization ... ventricular (RV) and left ventricular ... to reduce irregular ventricular intervals ...
... Contak Renewal 3 cardiac resynchronization ... therapy and cardiac resynchronization therapy. ... (RV) and left ventricular (LV) ... reduce irregular ventricular intervals during ...
... Contak Renewal 3 cardiac resynchronization ... therapy and cardiac resynchronization therapy. ... (RV) and left ventricular (LV) ... reduce irregular ventricular intervals during ...
... brain biopsy needle guide housing. MRI-compatible. ... mount. Placed through a standard 1.0 ... via autoclave Guide sphere assembly with a ... needles with barium sleeves. Sterile; single-use only ...
Medicine Products: